TSW
MYOV

Thompson Siegel & Walmsley’s Myovant Sciences Ltd. MYOV Stock Holding History

Thompson Siegel & Walmsley’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$281K – 688
2020
Q3 		$281K Buy
+20,000
New +$372K 0.01% 304

Other funds holding MYOV

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Thompson Siegel & Walmsley's MYOV Position: Q4 2020 in Review

Thompson Siegel & Walmsley sold out of Myovant Sciences Ltd. (MYOV) in Q4 2020, closing a stake of 20,000 shares — an estimated $281K sold.

Thompson Siegel & Walmsley first reported a position in MYOV in Q3 2020 and held it in 1 quarter. The position peaked at $281K in Q3 2020. 105 funds tracked by Wall St. Rank hold MYOV as of Q4 2020.

  • Thompson Siegel & Walmsley reported no remaining Myovant Sciences Ltd. position as of Q4 2020 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 20,000 Myovant Sciences Ltd. shares in Q4 2020, an estimated $281K.
  • Thompson Siegel & Walmsley first reported a position in Myovant Sciences Ltd. in Q3 2020 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's Myovant Sciences Ltd. position peaked at $281K in Q3 2020.
  • 105 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q4 2020.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2020, filed 8 Feb 2021.